(Q37768338)

22 August 2017

1 reference

title

Bowels control brain: gut hormones and obesity (English)

1 reference

22 August 2017

0 references

Benjamin C T Field

1

1 reference

PubMed ID

20585346

22 August 2017

Owais B Chaudhri

series ordinal

2

1 reference

PubMed ID

20585346

22 August 2017

Stephen R Bloom

series ordinal

3

1 reference

22 August 2017

29 June 2010

1 reference

Nature Reviews Endocrinology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

8

1 reference

22 August 2017

444-453

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.93

22 August 2017

0 references

cites work

The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Human distribution and release of a putative new gut hormone, peptide YY

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Differential regional metabolism of glucagon in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Long-term mortality after gastric bypass surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Efficacy of surgery in the management of obesity-related type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Structure and receptor binding of PYY analogs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Critical role for peptide YY in protein-mediated satiation and body-weight regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of peptide YY on gastric, pancreatic, and biliary function in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of circulating peptide YY on gallbladder emptying in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Gut hormone PYY(3-36) physiologically inhibits food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of PYY[3-36] in rodent models of diabetes and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Inhibition of food intake in obese subjects by peptide YY3-36

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of peptide YY3-36 on food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Supraphysiological doses of intravenous PYY 3-36 cause nausea, but no additional reduction in food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Distribution and release of human pancreatic polypeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Vagal, cholinergic regulation of pancreatic polypeptide secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

A receptor subtype involved in neuropeptide-Y-induced food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Characterization of the effects of pancreatic polypeptide in the regulation of energy balance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Pancreatic polypeptide stimulates gastric motility through a vagal-dependent mechanism in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Pancreatic polypeptide reduces appetite and food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Amylin reduces plasma glucagon concentration in cats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Synergy between amylin and cholecystokinin for inhibition of food intake in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon-like peptide-1 7-36: a physiological incretin in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Small-molecule agonists for the glucagon-like peptide 1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

GPR119 agonists for the treatment of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of glucagon on food intake and body weight in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Depression of food intake induced in healthy subjects by glucagon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effect of low glycogen on carbohydrate and energy metabolism in human muscle during exercise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Immunofluorescent localization of enteroglucagon cells in the gastrointestinal tract of the dog

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

The effect of oxyntomodulin (glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin suppresses appetite and reduces food intake in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Oxyntomodulin inhibits food intake in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Identification of cholecystokinin-secreting cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Regulation of ACTH secretory pathways in cultured pituitary cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Carbonic anhydrase and chemoreception in the cat carotid body

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Cholecystokinin elicits Satiety in Rats with Open Gastric Fistulas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

C-terminal octapeptide of cholecystokinin decreases food intake in man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Behavioral effects of AR-R 15849, a highly selective CCK-A agonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Leptin-mediated hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Ghrelin induces adiposity in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Circulating ghrelin levels are decreased in human obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Ghrelin increases food intake in obese as well as lean subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Influence of obesity and surgical weight loss on thyroid hormone levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.93

Glucagon acts in the liver to control spontaneous meal size in rats.

31 March 2020

1 reference

12 December 2020

Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men

1 reference

12 December 2020

Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans

1 reference

12 December 2020

Food fails to suppress ghrelin levels in obese humans.

1 reference

12 December 2020

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing

1 reference

12 December 2020

Hypothalamic influence on insulin and glucagon release in the rat

1 reference

12 December 2020

Ghrelin enhances appetite and increases food intake in humans

1 reference

12 December 2020

Integration of vagal afferent responses to gastric loads and cholecystokinin in rats

1 reference

12 December 2020

Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

Cholinergic dependence of gallbladder response to cholecystokinin in the guinea pig in vivo

1 reference

12 December 2020

Hepatic handling of pancreatic glucagon and glucose during meals in rats

1 reference

12 December 2020

Pancreatic glucagon response to an ordinary meal

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.93

1 reference

22 August 2017

1 reference

PubMed ID

20585346